Mark Chin is an Investment Director at Arix Bioscience. He joined Arix in 2016 with over 10 years of experience in the life sciences industry, and he currently sits on the boards of Iterum Therapeutics, Harpoon Therapeutics and OptiKira. He was previously a principal at Longitude Capital, where he focused on investments in both private and public biotechnology and medical technology companies. Prior to Longitude, he was a consultant at the Boston Consulting Group, where he was responsible for strategy and corporate development projects for pharmaceutical and biotechnology companies. Before BCG, Mark worked in corporate development at Gilead Sciences and market planning at Genentech.
Mark has an MBA from The Wharton School at the University of Pennsylvania, an M.S. in Biotechnology from the University of Pennsylvania, and a B.S. in Management Science from the University of California at San Diego.